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ARTICLE
Extension of the crRNA enhances Cpf1 gene editing
in vitro and in vivo
Hyo Min Park1, Hui Liu1, Joann Wu1, Anthony Chong1, Vanessa Mackley1, Christof Fellmann 2, Anirudh Rao2,
Fuguo Jiang2, Hunghao Chu1, Niren Murthy3 & Kunwoo Lee 1
Engineering of the Cpf1 crRNA has the potential to enhance its gene editing efficiency and
non-viral delivery to cells. Here, we demonstrate that extending the length of its crRNA at the
5′ end can enhance the gene editing efficiency of Cpf1 both in cells and in vivo. Extending the
5′ end of the crRNA enhances the gene editing efficiency of the Cpf1 RNP to induce non-
homologous end-joining and homology-directed repair using electroporation in cells.
Additionally, chemical modifications on the extended 5′ end of the crRNA result in enhanced
serum stability. Also, extending the 5′ end of the crRNA by 59 nucleotides increases the
delivery efficiency of Cpf1 RNP in cells and in vivo cationic delivery vehicles including polymer
nanoparticle. Thus, 5′ extension and chemical modification of the Cpf1 crRNA is an effective
method for enhancing the gene editing efficiency of Cpf1 and its delivery in vivo.
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C lass 2 CRISPR (clustered regularly interspaced shortpalindromic repeats)-encoded Cas effector proteins areRNA-guided endonucleases that can be programmed to
cleave DNA targets1–5. They have been broadly utilized to edit the
genomes of various organisms for both biotechnology and med-
ical purposes6–9. Among class 2 proteins, Streptococcus pyogenes
Cas9 (SpCas9) has been the most actively investigated. SpCas9
has been extensively engineered, optimized, and delivered both
in vitro and in vivo using a variety of different modalities and
methods10–16. By contrast, fewer optimizations have been
accomplished for the more recently discovered CRISPR-Cpf1.
Cpf1 proteins from the Acidaminococcus sp. BV3L6 (As),
Lachnospiraceae bacterium (Lb), and Francisella novicida U112
(Fn) organisms have several innate features that make them
attractive alternatives to SpCas917–20. First, Cpf1 has a unique
TTTV protospacer adjacent motif (PAM) recognition sequence
that expands genomic targeting beyond the guanosine-rich
sequences recognized by SpCas9 (NGG PAM)17,21–24. Second,
Cpf1 possesses an innate RNase activity that has been demon-
strated to facilitate the delivery of multiple CRISPR RNAs
(crRNAs) as a single-guide RNA (sgRNA)25–28. Third, Cpf1
proteins utilize a single crRNA (about 41 nucleotides)17, which is
much shorter than the 100-nucleotide-long crRNA-tracrRNA
chimera (sgRNA) used in SpCas929,30. The smaller size of the
Cpf1 crRNA facilitates the chemical synthesis and, thereby, the
chemical modification of the guide RNA31. Despite these
advantages, Cpf1 use in research and therapeutic settings is
limited. This may be due to the nuclease activity of Cpf1 or the
challenges associated with delivering Cpf1 in vitro and in vivo.
Engineering the crRNA of Cpf1 has great potential to enhance
both its gene editing efficiency and non-viral delivery to cells. The
sgRNA of SpCas9 has undergone extensive sequence, length, and
chemical optimizations to enhance gene editing
activity10,13,16,32–34. In contrast Cpf1 crRNA engineering remains
to be intensively explored, although a few studies have demon-
strated that modifications at the 3′ end can improve Cpf1
activity18,31.
We hypothesized that increasing the length of the crRNA scaf-
fold at the 5′ end can enhance the AsCpf1 RNP gene editing and
delivery. We selected the 5′ end for crRNA engineering because
various AsCpf1–crRNA complex structures show the 5′ terminal of
the crRNA scaffold to be largely exposed and potentially suitable for
engineering24,36. Also, it is unclear if the biochemically identified
minimal crRNA scaffold is the optimal crRNA scaffold for Cpf1-
mediated gene editing in eukaryotic systems17,25,28, and whether
extending the 5′ end could enhance editing efficiency. Lengthening
the crRNA scaffold at the 5′ end may also enhance the delivery of
the AsCpf1 RNP using cationic materials by increasing the com-
plex’s overall negative charge density.
Here, we demonstrate that extending the 5′ end of the crRNA
increases both the editing efficiency and delivery of AsCpf1
in vitro and in vivo. First, we show that a 2 to 59 nucleotide
extension to the 5′ end significantly increases AsCpf1-mediated
editing in electroporated cells. This enhancement is robust and
occurs in both immortalized and primary cells. Second, we
demonstrate that short 5′ extensions increase the tolerance of the
crRNA 5′ end to chemical modifications, which results in
enhanced serum stability. Finally, we show that AsCpf1 com-
plexed with a crRNA with a 59 nucleotide extension to the 5′ end
has dramatically increased gene editing efficiency both in vitro
and in vivo, after delivery with cationic delivery vehicles (Fig. 1).
Results and discussion
Extending the crRNA 5′ end increases Cpf1 RNP gene editing.
SpCas9 RNP exhibits robust gene editing in cells37–41. To assess
whether AsCpf1 RNP is also capable of achieving high gene
editing levels, we compared the two RNPs using a green fluor-
escent protein (GFP) reporter system. We selected a matched
protospacer sequence in GFP that could be recognized by both
AsCpf1 and SpCas9 in order to directly compare the two
nucleases (Fig. 2a). The RNP complexes were introduced into
HEK293T cells expressing the GFP gene under the control of a
doxycycline-inducible promoter (GFP-HEK) using electropora-
tion. Editing activity was determined by measuring the popula-
tion of GFP-negative cells, with GFP expression disrupted
through non-homologous end-joining (NHEJ)-mediated indel
mutations. AsCpf1 RNP exhibited lower gene editing than
SpCas9 in the electroporated cells (Fig. 2b).
We performed experiments to determine if having additional
nucleotides on the 5′ end of the Cpf1 crRNA could enhance its
gene editing efficiency. Engineering of the sgRNA scaffold has
been shown to enhance SpCas9 gene editing efficiencies13.
However, analogous investigations have not been conducted for
Cpf1. To determine if crRNA 5′ extensions affect Cpf1 gene
editing, we compared the activities of crRNAs with 5′ extensions
of various lengths using our GFP-HEK reporter system. GFP-
targeting crRNAs with 5′-end extensions of 4, 9, 15, 25, and 59
nucleotides were introduced into GFP-HEK cells by electropora-
tion as an RNP complex with AsCpf1. The sequences for the 4 to
25 nucleotide extensions were scrambled, and the 59 nucleotide
extension consisted of the AsCpf1 pre-crRNA17,25 preceded by a
scrambled RNA sequence with no homology to human genomic
sequences. The crRNAs with the 4 to 25 nucleotide 5′ extensions
all exhibited dramatically increased gene editing over the crRNA
with no extension. Cells electroporated with the unextended
crRNA were 30% GFP negative (crRNA), 4 to 25 nucleotide
extended crRNA were 55 to 60% GFP negative and 59 nucleotide
extended crRNA were 37% GFP negative (crRNA+59) (Fig. 2c).
The gene editing levels for the 4 and 25 nucleotide 5′ extended
crRNAs are comparable to that of the SpCas9 RNP-
electroporated cells (Fig. 2b).
5′ Extended crRNAs increase the HDR levels of AsCpf1. We
also examined whether the 5′ extension could increase homology-
directed recombination (HDR) rates in addition to NHEJ levels.
The AsCpf1 RNPs with crRNA containing various extensions
were introduced into GFP-HEK cells together with a single-
stranded oligonucleotide donor (ssODN) (Fig. 3a). HDR rates
were quantified using a restriction enzyme digestion assay40,42–44.
A twofold improvement in HDR was observed for both the 4 and
9 nucleotide extended crRNAs (17% HDR frequency for crRNA
+4 and 18% HDR frequency for crRNA+9 vs. 9% for control
crRNA in Fig. 3b).
Interestingly, cells treated with ssODN+Cpf1 RNP also had a
dramatic increase in the number of GFP-negative cells. The GFP-
negative cells generated from ssODN+Cpf1 RNP were caused by
frameshift mutations due to HDR and indel mutations caused by
NHEJ. The ssODN increased the percentage of GFP-negative
cells, which includes both NHEJ and HDR populations, from 30
to 46% for the unextended crRNA (crRNA), 55 to 92% for crRNA
+4, 58 to 90% for crRNA+9, and 37 to 58% for crRNA+59
(Fig. 3c). We performed additional experiments to determine if
the exogenously added DNA had to have homology to the Cpf1
RNP target site in order to enhance gene editing. AsCpf1 RNP
was electroporated into cells along with single-stranded DNA
(ssDNA) without any homology to the target sequence, and the
gene editing efficiency was measured. Similarly, the addition of
ssDNA without homology also increased the AsCpf1 editing
activity to approximately 90% for both extended crRNAs (Fig. 3d).
ssDNA can augment the editing efficiency of SpCas945, delivered
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via electroporation, and our results demonstrate that ssDNA can
augment editing with AsCpf1 as well. Additionally, the activity
enhancement of the 5′-end extension was synergistic with
exogenously added ssDNA and collectively the gene editing they
induced was close to a 100%, which is a level that had not been
reported previously. We also tested whether ssDNA could
increase the gene editing efficiency of Cpf1 after delivery into
cells via Lipofectamine. Supplementary Figure 1 shows that the
addition of ssDNA does not enhance the Cpf1 gene editing
efficiency, if Lipofectamine is used as the delivery method. This
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Fig. 1 crRNA with a 5′ extension enhances the gene editing efficiency and delivery of Cpf1. Extending the length of the Cpf1 crRNA at its 5′ end improves
the biological performance of the Cpf1 RNP. crRNA with a 5′ extension tolerates chemical modifications, and this results in greater serum stability. Cpf1
RNP with a 5′ extension has increased gene editing (both NHEJ and HDR) in cells after delivery via electroporation. In addition, Cpf1 RNP with a 5′
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Fig. 2 5′-End extensions of the crRNA enhance the gene editing of Cpf1 in HEK cells. a Sequence of the GFP protospacer that is targeted by both AsCpf1
and SpCas9. b Electroporation of SpCas9 and AsCfp1 RNP targeting the GFP-matched site demonstrate that SpCas9 can knock out genes more efficiently
than Cpf1. Mean ± SE, n= 4. *p < 0.05 by Student’s t test. c 5′ Sequence extension of crRNA increases Cpf1 gene editing in GFP-HEK cells. Cpf1 RNP+ with
various 5′ extended crRNAs were delivered to GFP-HEK cells using electroporation. Four nucleotide to twenty-five nucleotide extension significantly
increased editing efficiency. Mean ± SE, n= 3. **p < 0.01 by Student’s t test compared to crRNA control
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result limits the usage of ssDNA as an enhancer of gene editing to
the electroporation method.
We further investigated whether single-stranded RNA (ssRNA)
can enhance the gene editing efficiency of AsCpf1. ssDNA is
potentially problematic to use for enhancing AsCpf1 gene editing
activity because ssDNA can potentially integrate into the genome
and cause genomic damage; in contrast, ssRNA cannot integrate
into the genome, and would be much safer to use. GFP-HEK cells
were electroporated with Cpf1 RNP and two different ssRNAs (9
and 100 nucleotides) and the resulting levels of gene editing were
determined. Two 100 nucleotide ssRNAs with slight sequence
variation both dramatically increased the gene editing efficiency
of Cpf1, resulting in a twofold improvement, whereas the 9
nucleotide ssRNA induced only a 10% enhancement in gene
editing efficiency (Fig. 3e). These results suggest that 100
nucleotide ssRNA can be potentially used as a gene editing
enhancer for Cpf1 RNP, and provides a safe alternative to ssDNA.
Extended crRNAs enhance editing efficiency in primary cells.
We performed gene editing experiments with Cpf1 RNP com-
plexed to 5′ extended crRNAs, in primary mouse myoblasts, to
determine if the gene editing enhancements seen in GFP-HEK
cells could be applied to other cell types. We choose primary
mouse myoblasts as a second test bed because of their importance
in treating genetic muscular dystrophies, including Duchenne
muscular dystrophy. Primary myoblasts isolated from the Ai9
mouse (ai9 myoblasts)46,47 were electroporated with AsCpf1 RNP
complexed with crRNAs with and without 5′ extensions, and
resulting levels of gene editing were determined. The Ai9 mouse
is a transgenic mouse strain, which contains a tdTomato reporter
gene that has stop codons in all three reading frames coupled to a
triple poly(A) signal (Fig. 4a). The AsCpf1 spacers were designed
to introduce multiple breaks into the reporter gene, which would
remove the stop sequences by deletion, allowing for genetic
editing to be monitored via the expression of tdTomato (a red
fluorescent protein, RFP), either through fluorescence microscopy
(Fig. 4a) or flow cytometry (Fig. 4b).
The extended crRNAs showed a 25–60% increased gene editing
over the unextended crRNA in primary myoblasts. Myoblasts
treated with unextended crRNA were 12% RFP positive, 2
nucleotide extended crRNA were 15% RFP positive, 9 nucleotide
extended crRNA were 20% RFP positive, and 59 nucleotide
extended crRNA were 18% RFP positive (Fig. 4b). Additionally,
the effects of ssDNA or ssRNA were also tested in primary
myoblasts, and both ssDNA and ssRNA (100 nucleotide length)
enhanced the gene editing efficiency of Cpf1 RNP in primary
myoblasts (Fig. 4c).
Finally, we investigated if 5′ extended crRNAs could enhance
the ability of the Cpf1 RNP to edit an endogenous gene,
SERPINA1, as a testbed. SERPINA1 was selected for further
investigation because mutations in the SERPINA1 gene cause α1-
anti-trypsin deficiency48,49, which makes it a target for ther-
apeutic gene editing. Cpf1 with either crRNA or crRNA+9,
targeting the SERPINA1 gene, were transfected into HepG2 cells
via electroporation. Figure 4d shows that Cpf1 RNP with crRNA
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Fig. 3 Single-stranded DNA has synergistic effects with 5′ extended crRNAs and enhances both NHEJ and HDR in HEK cells. a Cpf1 RNP and ssODN were
electroporated into cells and the HDR and NHEJ rates were determined. b The HDR frequency in GFP-HEK cells is enhanced with Cpf1 RNP+. The donor
ssODN contained a restriction enzyme site, which was used for a restriction enzyme digestion assay to determine the HDR frequency. Mean ± SE, n= 3. *p
< 0.05, **p < 0.01 by Student’s t test compared to crRNA control. c GFP knockout efficiency of Cpf1 RNP+ was further improved in GFP-HEK cells when
ssODN was delivered together with electroporation. Cpf1 RNP+ with various 5′ extended crRNAs and donor ssODN were delivered to GFP-HEK cells using
electroporation. Mean ± SE, n= 3. **p < 0.01 by Student’s t test compared to crRNA control. d The GFP knockout efficiency of Cpf1 RNP+ was improved in
GFP-HEK cells when ssDNA was exogenously added. Cpf1 RNP+ with various 5′ extended crRNAs and random 100 nt ssDNA without homology to the
target sequence were delivered to GFP-HEK cells using electroporation. ssDNA enhanced gene editing efficiency of Cpf1 RNP close to 90%. Mean ± SE, n
= 3. **p < 0.01 by Student’s t test compared to each without ssDNA control. e ssRNA enhances the knockout efficiency of Cpf1 RNP in GFP-HEK cells. Cpf1
RNP and random ssRNAs (without sequence similarity) were delivered to GFP-HEK cells using electroporation. Mean ± SE, n= 3. *p < 0.05, **p < 0.01 by
Student’s t test compared to crRNA control
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+9 had an enhanced NHEJ efficiency in comparison to wild-type
crRNA. Collectively, these results suggest that the enhancing gene
editing effects of the 5′ crRNA extensions are broadly applicable
across genetic targets and cell types.
The 5′ crRNA extension tolerates chemical modifications.
Chemical modification of crRNAs and sgRNAs have great
potential for improving the gene editing efficiency of CRISPR/Cas
proteins. For example, chemical modification of sgRNAs at the 5′
and 3′ end improves the SpCas9 activity in both ex vivo and
in vivo settings10,33,34,50, and chemical modification of Cpf1
crRNA at its 3′ end also results in a modest enhancement in gene
editing activity31. However, the 5′ end of the Cpf1 crRNA has
been intractable to chemical modifications, and modification
results in a loss of nuclease activity31,51. Thus, it has been chal-
lenging to improve the activity of the Cpf1 RNP with chemically
modified crRNAs due to their low tolerance towards chemical
modifications.
We therefore investigated if extending the crRNA at its 5′ end
increases its tolerance to chemical modifications. Three different
chemical modifications were investigated on crRNAs with
extension. In particular, we introduced 2′ O-methyl modifica-
tions, phosphorothioate linkages, and deoxynucleotide ribose
groups to the crRNA extensions (Fig. 5a). We chose these
modifications because they have enhanced the stability of various
RNAs, including small interfering RNAs (siRNAs) and
SpCas9 sgRNAs10,33,50,52–55. The chemical modification applied
to the 5′ extended crRNA are shown in Fig. 5. Three different
chemical modification of the 5′ extended crRNAs were
investigated. These were: (1) a crRNA with the first 3 of the 4
nucleotides extended with 2′-O-methyl nucleotides and 3′
phosphorothioate linkage (MS), (2) a crRNA with a deoxynu-
cleotide at the 9th position of the 9 nucleotide 5′ extended crRNA
(9dU), and (3) a crRNA with a 3′ phosphorothioate linkage at all
9 nucleotides plus a deoxynucleotide at the 9th position of the 9
nucleotide 5′ extended crRNA (9S). Cpf1 RNP with crRNAs that
had extensions and chemical modifications were electroporated
into GFP-HEK cells and the gene editing activity was determined
by flow cytometry. Extended crRNA with chemical modifications
had similar activity to unmodified extended crRNA (41–46%
GFP-negative cells) (Fig. 5b). Also, these crRNAs were examined
using a blue fluorescent protein (BFP) expressing HEK293T cell
line (BFP-HEK). Similar to the above studies with the GFP-HEK
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cells, the 5′ extensions increased the gene editing efficiency of
AsCpf1 and the tolerance of the 5′ end of the crRNA for chemical
modifications (Supplementary Fig. 2). These results demonstrate
that 5′ chemical modifications of the crRNA are possible without
damaging the activity, if the 5′ end of the crRNA is extended.
A key benefit of using chemically modified crRNAs is that they
are more stable to hydrolysis by serum nucleases. Therefore, the
serum stability of the 5′ chemically modified crRNAs was
investigated. 5′ Chemically modified crRNAs were incubated in
diluted fetal bovine serum (FBS) and their degradation was
analyzed via gel electrophoresis. Figure 5c, d show that unmodified
crRNAs rapidly degrade in serum, whereas crRNA+9S, which
contains a phosphorothioate backbone, is significantly more stable
to hydrolysis in serum. In addition, we investigated if 5′ modified
crRNAs could enhance the ability of Lipofectamine to transfect
Cpf1 RNP, due to its ability to protect the crRNA from nucleases in
cells and in serum. Cpf1 with crRNA+9S was more efficient at
editing genes in cells than crRNA+9 by 40%, and this suggests that
5′ crRNA chemical modifications, enabled by 5′ crRNA extension,
will have numerous applications in gene editing (Fig. 5e).
The crystal structure of Cpf1 RNP has recently been solved and
demonstrates that the AsCpf1 protein forms numerous interac-
tions with the phosphodiester backbone of the crRNA24,36. 5′
Chemical modifications of the unextended crRNA therefore has a
high chance of disrupting important interactions between the
crRNA and the Cpf1, resulting in a disruption of AsCpf1 gene
editing activity. In contrast, crRNA with 5′ extensions appear to
tolerate chemical modifications because the nucleotides interact-
ing with the AsCpf1 protein are not modified. These results
provide a methodology for introducing chemical modifications at
the 5′ end of the crRNA, which can potentially enhance Cpf1
delivery for ex vivo and in vivo therapeutic applications10,31,50.
crRNA extension enhances delivery to cells by cationic lipid.
Unlike SpCas9 that has been delivered with cationic lipids like
Lipofectamine38,56,57, Cpf1 has not been delivered with cationic
delivery vehicles. This may be because of the potentially poor
interaction between Lipofectamine and the Cpf1 RNP due to the
low negative charge of the RNP complex. In contrast to the
SpCas9 sgRNA (100 nt), the Cpf1 crRNA is significantly shorter
(41 nt). A shorter RNA may reduce the ability of the Cpf1–crRNA
complex to interact with cationic lipids. As crRNA 5′ end toler-
ates extensions of various lengths (Figs. 2, 3, 4), we examined
whether 5′-end extensions enhanced AsCpf1 gene editing in cells
using cationic lipids. AsCpf1 RNP complexed with crRNAs
containing a 0, 9, or 59 nucleotide extensions were introduced
into GFP-HEK cells using Lipofectamine 2000. Both the 9 and 59
nucleotide extended crRNAs exhibited increased gene editing
over the unextended crRNA: unextended crRNA cells were 8%
cr
RN
A
cr
RN
A
+4
cr
RN
A
+4
MS
cr
RN
A
+9
cr
RN
A
+9
scr
am
ble
d
cr
RN
A
+9
du
cr
RN
A
+9
S
0
20
40
60
G
FP
– 
(%
)O
OCH3
O
O
OHO
O
PO S–
O
O
OH
O
O
HO
O
PO O–
O
O
OH
O
O
HO
O
PO S–
O
0
10
20
30
40
50
*
**
**
G
FP
– 
(%
)
cr
RN
A
cr
RN
A
+9
cr
RN
A
+9
S
No
 se
rum c
rR
NA
cr
RN
A
+9
cr
RN
A
+9
dU
cr
RN
A
+9
S0
50
100
R
el
at
iv
e 
cr
R
N
A 
am
ou
nt
 (%
)
crRNA 41 nt
50 nt
50 nt
50 nt
crRNA+9dU
crRNA+9S
crRNA+9
0
a
c d e
b
15 30 60
Serum incubation time (min)
5′ 3′
3′
3′
5′
5′
crRNA
crRNA+4
crRNA+9 MS 9dU
2′-deoxy
9s
Phosphorothiate
2′-deoxy
Fig. 5 Chemical modifications on the 5′ extended crRNA are well tolerated and enhance serum stability. a crRNAs with 4 and 9 nt extensions, using a
variety of sequences: MS is 2′-OMe 3′-phosphorothioate modifications on the first three nucleotides from the 5′ end,+9dU is 2′-deoxy modification on the
9th nucleotide from the 5′ end, +9S is phosphorothioate modifications on the first 9 nucleotides from the 5′ end on top of 2′-deoxy modification on the 9th
nucleotide. b Chemical modifications on extended crRNAs are well tolerated and show similar Cpf1 gene editing efficiency to unmodified crRNAs in GFP-
HEK cells. Mean ± SE, n= 3. All extended crRNAs had a statistically significant difference to unmodified crRNA with a p value less than 0.01 by Student's t
test. c crRNA with phosphorothioate backbone modification (crRNA+9S) has enhanced serum stability. crRNAs with and without chemical modification
were incubated with serum and analyzed by gel electrophoresis. d Quantification of crRNAs after 15 min incubation in serum. Relative band intensity of
crRNA, normalized to crRNA without serum incubation. Mean ± SE, n= 3. **p < 0.01 by Student’s t test compared to crRNA control. e crRNA with a 9 nt
extension that has been modified with a phosphorothioate backbone (crRNA+9) has enhanced Cpf1 gene editing efficiency after delivery with
Lipofectamine. Cpf1 RNPs with various crRNAs were delivered with Lipofectamine to GFP-HEK cells and the GFP-negative population was quantified. Mean
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GFP negative (crRNA), the 9 nucleotide extended crRNA cells
were 18% GFP negative (crRNA+9), and the 59 nucleotide
extended crRNA cells were 37% GFP negative (crRNA+59)
(Fig. 6). In addition, crRNA+9, crRNA+15, and crRNA+25 were
tested with Lipofectamine and increased the Cpf1 gene editing
efficiency in a length-dependent manner (Supplementary Fig. 3).
Next, to ascertain if there is a specific 5′-extension sequence
requirement for this enhancement, three different 59 nucleotide
5′ extensions were compared. The first and original 59 nucleotide
extended crRNA is described above and contains one AsCpf1
pre-crRNA (crRNA+59), the second 59 nucleotide extended
crRNA contains four AsCpf1 pre-crRNA sites in tandem (crRNA
+59-D2), and the third 59 nucleotide extended crRNA contains
the FnCpf1 pre-crRNA17,28,58 preceded by a scrambled DNA
sequence with no homology to any sequence in the human
genome (crRNA+59-D3) (Fig. 6c). RNP complexes with these
crRNAs were delivered using Lipofectamine 2000. All three 5′
extensions showed equivalent editing activity: crRNA+59 cells
were 32% GFP negative, crRNA+59-D2 cells were 30% GFP
negative, and crRNA+59-D3 cells were 27% GFP negative
(Fig. 6c). This suggests that there is not a stringent sequence
requirement for the 5′-extension enhancement, similar to
previous findings with the 9 nucleotide extended crRNAs with
electroporated cells (Fig. 2). Additionally, these results provide
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evidence supporting the above hypothesis that increasing the
negative charge density on the crRNA and, thereby, the
AsCpf1–RNP complex can enhance the delivery of AsCpf1 to
cells by cationic lipids.
We performed experiments to determine the mechanism by
which the 5′ extended crRNAs enhanced the gene editing
efficiency of the Cpf1 RNP. First, we tested whether the extended
crRNAs enhance the inherent nuclease activity of Cpf1, using an
in vitro DNA cleavage assay. We observed no activity difference
between the three crRNAs tested, wild-type crRNA, cRNA+9, and
crRNA+59 with 15 and 60 min incubation times (Supplementary
Figs. 4 and 5). crRNA+59 even had slower DNA cleavage than
wild-type crRNA when the incubation time was only 5 min. This
result suggests that crRNA extension does not enhance the
inherent nuclease activity of the Cpf1 RNP. We also investigated
if 5′ extended crRNAs enhanced the gene editing activity if the
Cpf1 was delivered by plasmid rather than as an RNP. Cpf1
plasmid was transfected 24 h prior to electroporation of the
crRNAs and the gene editing activity was determined. Extended
crRNAs showed no improvement in gene editing efficiency when
the Cpf1 was produced from plasmids (Supplementary Fig. 6).
Finally, we labeled the crRNAs with a fluorescence dye to
determine if the extended crRNAs had enhanced uptake in cells
after delivery via either electroporation or Lipofectamine.
Electroporation of the Cpf1 RNPs resulted in above 90% of
the cells being positive for the dye-crRNA and showed highly
efficient delivery regardless of the crRNA length. On the other
hand, the delivery efficiency of Cpf1 RNP with Lipofectamine
was dependent on the length of the crRNA, and extended
crRNAs were delivered into HEK 293T cells more efficiently
than wild-type crRNA (Fig. 6d). The net charge of a
macromolecule is a critical parameter for efficient interaction
with Lipofectamine. Extension of the crRNA significantly
increases the net negative charge of the Cpf1 RNP, which
should result in more efficient interaction with Lipofectamine
and efficient delivery into cells.
crRNA extension enhances Cpf1 delivery by cationic polymers.
Cationic polymers have been investigated for CRISPR delivery
because of their ability to efficiently deliver CRISPR components
to a variety of cell types and animal models46,51,59. Poly(aspartic
acid) derivates are cationic polymers with well-established ability
to deliver siRNA and the SpCas9 RNP in vivo46,60,61. Similarly to
cationic lipids, we hypothesized that the 5′ extended crRNA can
enhance cationic polymer-based delivery of AsCpf1 RNP to cells.
We performed experiments to determine whether the 5′ extended
crRNA could also boost the delivery of the AsCpf1 RNP to cells
using PAsp(DET). AsCpf1 RNPs with either the 9 or 59
nucleotide 5′ extended crRNA were introduced to GFP-HEK cells
using PAsp(DET). Immunofluorescence microscopy and flow
cytometry were used to detect the GFP-negative population as
surrogate readouts for delivery (Fig. 6e, f, respectively). Similar to
the above findings with cationic lipids, the 59 nucleotide 5′
extension also enhanced PAsp(DET)-mediated delivery of
AsCpf1 RNP to cells by twofold. The unextended crRNA
(crRNA) was 8% GFP negative, the 9 nucleotide extended crRNA
(crRNA+9) was 10% GFP negative, and the 59 nucleotide
extended crRNA (crRNA+59) was 18% GFP negative (Fig. 6f).
Collectively, the findings from this section, along with previous
sections, suggest that the 59 nucleotide 5′ extension of the crRNA
is a versatile tool for increasing the delivery of AsCpf1 RNP to
cells using cationic materials.
Efficient in vivo delivery of Cpf1 by polymer nanoparticles.
There is great interest in developing technologies that can safely
and effectively deliver the Cpf1 RNP in vivo. Currently, the only
method for delivering Cpf1 in adult mammals is through the use
of viruses25. However, compared to viral-based methods, direct
delivery of the Cpf1 RNP has several advantages because it avoids
the immunogenicity problems associated with using viruses62–66,
is straightforward to manufacture67–70, and potentially generates
low levels of off-target DNA damage35,71. Non-viral delivery
vehicles that can deliver the Cpf1 RNP in vivo therefore have the
potential to dramatically accelerate the development of Cpf1
therapeutics.
Since the crRNA+59 enhanced delivery and gene editing of
AsCpf1 RNP in vitro, we conducted studies to assess whether this
extension could also bolster in vivo delivery and editing with
either polymer nanoparticles or Lipofectamine. Among a number
of poly(aspartic acid) derivative polymers (PAsp analogs)
synthesized, one PAsp derivative polymer was identified that
could efficiently deliver Cpf1 to myoblasts in vitro and was
investigated in vivo. Ai9 mice were given one intramuscular
injection of polymer or Lipofectamine combined with either Cpf1
RNP or Cpf1 RNP+59. Two weeks after the injection, the
expression of tdTomato (red fluorescence) was imaged in 10 µm
sections of the gastrocnemius muscle (Fig. 7a). The Cpf1 RNP
with a crRNA extension was more efficiently delivered by both
Lipofectamine and polymer and efficient gene editing of its target
sequence was observed via expression of tdTomato in muscle
sections. Additionally, we investigated how broad the region of
editing in the muscle was with the Cpf1 RNP+59 after delivery
with polymer nanoparticles. tdTomato was expressed along the
muscle fibers in the gastrocnemius muscle, and the polymer
nanoparticle+ Cpf1 RNP+59 formulation edited an area several
millimeters away from the injection site (Fig. 7b).
The extension of the crRNA of Cpf1 allowed efficient
nanoparticle formulation with cationic polymers and effective
delivery of Cpf1 into the muscle tissue. As a non-viral delivery
method, polymer nanoparticles have great clinical potential,
because of their low toxicity and low-cost manufacturing process.
The enhanced delivery of Cpf1 RNP with polymer nanoparticles
in vivo, enabled by crRNA extension, bolsters the value of Cpf1 as
a potential therapeutic for treating human diseases.
The crRNA 5′ extensions presented here are straightforward to
apply and broadly applicable across cell types. As such, they are
powerful tools for developing new gene editing reagents and
therapeutics. We demonstrate that extension of the 5′ end of the
Cpf1 crRNA increases the gene editing efficiency of Cpf1 RNP in
cells. In addition, extending the 5′ end of the Cpf1 crRNA also
enables chemically modified bases to be incorporated into the
crRNA, which is impossible to do at the 5′ end without a crRNA
extension. Finally, extension of the Cpf1 crRNA significantly
increases the negative charge density of the Cpf1 RNP and
significantly improves the ability of cationic materials to deliver
the Cpf1 RNP in vitro and in vivo. We envision that polymer
nanoparticle–Cpf1 RNP complexes will enable numerous appli-
cations in therapeutic gene editing.
Methods
Materials. SpCas9 and AsCpf1 were purchased from the MacroLab in UC Ber-
keley. Proteins were stored in 50 mM HEPES (4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid) at pH 7.5 with 300 mM NaCl, 10% glycerol, and 100 μM
tris(2-carboxyethyl) phosphine at −80 °C. PAsp(DET) polymer was synthesized
using the following literature references46,60,61. Phusion High-fidelity DNA Poly-
merase was purchased from NEB (Ipswich, MA, USA). The MEGAscript T7 kit,
the MEGAclear kit, the PageBlue solution, the propidium iodide, and the PureLink
genomic DNA kit were purchased from Thermo Fisher (Waltham, MA, USA).
Mini-PROTEAN TGX (Tris-Glycine eXtended) gels (4–20%) were purchased from
Bio-Rad (Hercules, CA, USA). Dulbecco’s modified Eagle's medium (DMEM),
non-essential amino acids, penicillin–streptomycin, Dulbecco's phosphate-buffered
saline (PBS), and 0.05% trypsin were purchased from Life Technologies (Carlsbad,
CA, USA).
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Synthesis of gRNAs. crRNAs and sgRNAs were purchased from IDT or synthe-
sized using in vitro transcription. The sequences of gRNA are given in the Sup-
plementary Data. The DNA template used for in vitro transcription was produced
by overlapping PCR. Briefly, the forward primer and reverse primer (1 μM) were
mixed with Phusion DNA Polymerase (NEB) and PCR amplification was con-
ducted. The DNA template was purified with a PCR clean-up kit. The Megascript
T7 RNA polymerase kit (Thermo Fisher) was used to make gRNAs. Polyacrylamide
gel extraction was conducted to make sure uniform sized gRNAs were produced.
The concentration of purified gRNA was determined with a Nanodrop 2000
(Thermo Fisher Scientific) and the final gRNA products were stored at −80 °C.
HEK293T reporter cell lines. HEK293T cells (293FT; Thermo Fisher Scientific),
and derived cell lines, were grown in DMEM (Corning Cellgro, #10-013-CV)
supplemented with 10% FBS (Seradigm #1500-500), and 100 U/ml penicillin and
100 μg/ml streptomycin (Pen-Strep; Life Technologies Gibco, #15140-122) at 37 °C
with 5% CO2. Monoclonal HEK-RT3-4 reporter cells, here referred to as “GFP-
HEK,” were generated through low-copy transduction of HEK293T human
embryonic kidney cells with the amphotropic-pseudotyped retrovirus RT3GEPIR-
sh.Ren.71372, comprising an all-in-one Tet-On system enabling doxycycline-
controlled EGFP expression. After puromycin (2.0 μg/ml) selection of transduced
HEK239Ts, 36 clones were isolated and individually assessed for (i) growth
characteristics, (ii) homogeneous morphology, (iii) sharp fluorescence peaks of
doxycycline- (1 μg/ml) inducible EGFP expression (Guava EasyCyte, Millipore),
(iv) relatively low fluorescence intensity to favor clones with single-copy reporter
integration, and (v) high transfectability. HEK-RT3-4 cells are derived from the
clone that performed best in these tests (Supplementary Fig. 7). BFP-HEK cells
were generated by transfecting HEK cells with a BFP-containing lentivirus,
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Fig. 7 Cpf1 RNP+59 enhances the delivery efficiency of Cpf1 RNP in vivo using polymer nanoparticle in Ai9 mice. a Fluorescence image of the entire
gastrocnemius muscle cross-section that was injected with Cpf1 RNP. Cpf1 RNP efficiently induces gene deletions and robust expression of tdTomato in
Ai9 mice after delivery with PAsp derivative polymer or Lipofectamine. Width of each image is 6.5 mm. b Serial fluorescence images of the entire
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followed by fluorescence-activated cell sorting-based enrichment using the protocol
published by Richardson et al.45. HEK cells were plated at a density of 5 × 104 cells
per well in a 24-well plate, a day before transfection experiments.
Isolation and culture and transfection of primary myoblasts. All animal studies
were performed according to authorized protocols and animals were treated fol-
lowing the policies of the Animal Care and Use Committee of the University of
California, Berkeley. Primary myoblasts were obtained from Ai9 mice following the
previously reported protocol from Conboy and co-workers10 and Rando Yin
et al.11. Briefly, the gastrocnemius and tibialis anterior muscles were harvested and
incubated for 30 min in a digest medium (Thermo, #17703034). Myoblasts were
cultured on collagen-coated plates with myoblast culture medium (Ham’s F-10
Nutrient mixture, 20% FCS, 2.5 ng/ml basic fibroblast growth factor,
penicillin–streptomycin), with replacement every 24 h. Cpf1 RNPs were transfected
using electroporation. After transfection, cells were cultured for an additional
6 days, and the editing efficiency was detected by flow cytometry.
Electroporation. Cells (2×105 cells after counting) were detached by Accutase and
spun down at 600 ×3 g for 3 min and then washed with PBS. The Amaxa 96-well
Shuttle system was used for electroporation following the manufacturer’s protocol.
Cpf1 RNP or Cas9 RNP with or without DNA (Cpf1: 50 pmol; crRNA: 50 pmol,
Cas9: 50 pmol, sgRNA: 50 pmol, with or without ssDNA/ssRNA: 50 pmol) were
prepared in 10 µl of electroporation buffer. After the electroporation, the cells were
incubated at 37 °C in tissue culture plates with 500 μl of culture media. The culture
media were changed 16 h after the electroporation.
Lipofection. Cpf1 RNP (50 pmol of Cpf1 and 50 pmol of crRNA) or Cas9 RNP
(50 pmol of Cas9 and 50 pmol of sgRNA) was mixed with 2 µl of Lipofectamine
2000 in a 40 µl total volume in OptiMEM. The lipofection was conducted in
OptiMEM media without serum, and an equal volume of 2× growth media was
added to the cells after 4 h of lipofection to minimize cytotoxicity. The medium was
changed 16 h after the lipofection and the cells were incubated for several days until
further fluorescence analysis. ssDNA (1 µg) was added to Cpf1 RNP solution for
ssDNA experiments. For the cell delivery quantification experiment, crRNAs
labeled with Atto 495 were delivered with the same method. One hour after
transfection, the medium was removed and cells were washed with PBS. Cells were
cultured additional 3 h in culture medium before flow cytometry analysis.
Polymer transfection. Cpf1 RNP (50 pmol of Cpf1 and 50 pmol of crRNA) or
Cas9 RNP (50 pmol of Cas9 and 50 pmol of sgRNA) was mixed with 10 µg of PAsp
(DET) that was prepared in 20 µl of 20 mM HEPES buffer. Transfection was
conducted in OptiMEM media without serum, and an equal volume of 2× growth
media was added to the cells after 4 h of lipofection to minimize cytotoxicity. The
medium was changed 16 h after the lipofection and the cells were incubated for
several days and analyzed for fluorescence analysis.
Serum stability assay. One microgram of RNA was prepared in 10 µl of PBS
containing 5% FBS and incubated at 37 °C for 0, 15, 30, or 60 min. Ten microliters
of Gel Loading Buffer II (Thermo) was then added and heated at 70 °C for 5 min to
denature RNA and proteins. RNA samples were loaded into a 4–20% TGX to
detect intact RNA. Quantitative analysis was obtained by three independent
experiments and band intensity quantification was conducted using the ImageLab
software (Bio-Rad).
SERPINA1 gene editing detection with droplet digital PCR. HepG2 cells were
transfected using the electroporation method described above. Four days after the
electroporation, gDNA was extracted and digested using HindIII (NEB) at 37 °C
for 1 h. HepG2 cells were purchased from the Cell Culture Facility at UC Berkeley
(Original source: ATCC HB-8065). In each ddPCR reaction, 50–100 ng DNA,
ddPCR primers, probes, 10 μl of ddPCR Supermix (No dUTP) (Bio-Rad), and
nuclease-free water were added, to generate a 20 μl volume, and mixed well.
Reaction mixtures, together with 70 μl QX200 Droplet generation oil, was loaded
into the appropriate wells of an 8-channel droplet generation cartridge, according
to the instruction manual. The cartridge was placed in the QX200™ Droplet
Generator to generate the droplets, which were then transferred to a 96-well plate
and amplified by standard PCR. Cycling conditions were: 95 °C for 5 min, 40 cycles
of 94 °C for 30 s, and 58 °C for 1 min, followed by 98 °C for 10 min and final hold at
4 °C. The ramp rate was 2 °C/s. After thermal cycling, plates were placed in
QX200™ Droplet Reader for data acquisition.
In vitro cleavage gel. Template GFP DNA that was synthesized via PCR (25 nM)
was cleaved with Cpf1 RNP with and without extension of the crRNA (165 nM) in
a 10 µl solution for 5, 15, and 60 min. Gel electrophoresis of the cleavage samples in
Tris/Borate-sodium dodecyl sulfate buffer separated the template from the cleavage
products. Nucleic acid staining was conducted with Sybr Safe and then the gel was
imaged and the individual bands were quantified with ChemiDoc MP using the
ImageLab software (Bio-Rad).
Representative images. Representative images and uncropped images can be
found in Supplementary Figs. 8–14.
Cpf1 plasmid transfection. Cpf1 plasmid18 was transfected into GFP-HEK cells
(2 × 105 cells) by mixing 1 µg of plasmid and 1 µl of Lipofectamine 2000 in
OptiMEM. After 24 h transfection, electroporation was conducted for crRNA
delivery.
Flow cytometry analysis and fluorescence microscopy. Flow cytometry (Attune
Nxt Flow Cytometer, Thermo Fisher Scientific) was used to quantify the expression
levels of BFP from BFP-HEK cells and of EGFP from GFP-HEK cells after
transfection with potential editing reagents. The BFP-HEK cells were analyzed
7 days after transfection. The GFP-HEK cells were induced with doxycycline (1 µg/
ml) 48 h after transfection. Fluorescence observation or quantification was con-
ducted 48 h after the induction. Hoechst staining was conducted to visualize the
nucleus, and fluorescence images were taken with a Zeiss Axioscope fluorescent
microscope and analyzed with ImageJ. For flow cytometry, the cells were washed
with PBS and detached by Accutase.
Analysis of genome editing efficiency. HDR efficiency was quantified by the
restriction enzyme digestion of PCR-amplified target genes. Donor ssODN was
designed to insert restriction enzyme sites, cleavable by ClaI, into the sequence that
Cpf1 targets. The PCR amplicon of the BFP or GFP gene was incubated with the
ClaI restriction enzyme (10 U) for 2 h at 37 °C. The products were analyzed by gel
electrophoresis using a 4–20% Mini-PROTEAN TGX Gel (Bio-Rad) and stained
with SYBR Green (Thermo Fisher). Individual band intensity was quantified using
ImageLab and the HDR efficiency was calculated using the following equation:
(b+ c) / (a+ b+ c) × 100 (a= uncleaved PCR amplicon, b and c= the cleavage
products).
Gene editing in the muscle of Ai9 mice. All animal studies were performed
according to authorized protocols and animals were treated following the policies
of the Animal Care and Use Committee of the University of California, Berkeley.
Three groups of 4-week-old Ai9 mice (Jackson Laboratory, #007909) were used in
this experiment, including control (no injection, n= 1), non-extended crRNA
group (n= 3), and extended crRNA group (n= 3). Both male and female mice
were chosen randomly for experiments and analysis was conducted in a non-
blinded way. Cpf1 (200 pmol), crRNAs (200 pmol), and 40 µg PAsp derivative
polymer were mixed and incubated for 2 min at room temperature. These nano-
particles were injected into gastrocnemius muscles (20 µl per muscle) using a 35 g
WPI NanoFil syringe. Two weeks after the injection, the muscles were harvested,
mounted in OCT, and flash frozen. Ten micrometer sections were cut using a
cryostat. Entire gastrocnemius muscle was sectioned into hundreds of sections and
observed throughout 6 mm range to understand how broad the effects of gene
editing were. Pictures were taken by Opera Phenix High-Content Screening System
with ×20 water objective and 10 areas were combined. Image J was applied to
analyze the area of red fluorescence and total area. For Lipofectamine treatment,
the non-extended crRNA group (n= 1) and extended crRNA group (n= 1) were
injected with Cpf1 RNP with Lipofectamine: Cpf1 (200 pmol), crRNAs (200 pmol),
and Lipofectamine 2000 (8 µl) were mixed and incubated for 5 min at room
temperature.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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